Chikungunya Vaccine Digital Symposium Scheduled for July 9th
A specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with a significant unmet medical need announced it would host a virtual symposium titled, “Developing new vaccines to protect against infectious diseases at home and abroad” on July 9, 2021, at 14:15 CEST at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
The symposium on chikungunya will be chaired by Katrin Dubischar, VP Program Director Chikungunya Vaccine at Valneva.
To Valneva’s knowledge, VLA1553 is currently the only chikungunya vaccine candidate in Phase 3 clinical trials that targets long-term protection with a single administration. The program was granted Fast Track designation by the U.S. FDA in December 2018 and PRIME designation by the European Medicines Agency in October 2020.
Prof. Thomas Jelinek, renowned key opinion leader and Medical Director of Berlin Centre for Travel and Tropical Medicine, will present on chikungunya disease and results of the Phase 1 study of Valneva’s single-dose chikungunya vaccine candidate VLA1553.
To digitally attend the ECCMID conference and participate in Valneva’s symposium, you can register at this weblink.